Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
November 1, 2004
- No Consensus on "Method Patents" in Medical Field
November 1, 2004
- Alesion Dry Syrup to Be Approved
November 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 1, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 1, 2004
- PRESS SEMINAR
November 1, 2004
- Health Science Technology Transfer Center Starts Full Activities
November 1, 2004
- Fuji Biomedix, SCAS Tie Up in Drug Development Support Business
November 1, 2004
- NEW PRODUCTS
November 1, 2004
- Business Forecast
November 1, 2004
- BUSINESS NEWS IN BRIEF
November 1, 2004
- 1st 3Qtrs Business Results
November 1, 2004
- NBI Obtains Import Approval of Spiriva
November 1, 2004
- Semi-annual Business Results
November 1, 2004
- Pegintron Receives Import Approval
November 1, 2004
- Sandostatin Approved for GI Symptoms due to GI Tract Obstruction
November 1, 2004
- JT Licenses Hyperlipidemia Drug to Roche
November 1, 2004
- PRESS SEMINAR
November 1, 2004
- Eisai Machinery Starts Operations on Oct. 1
November 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 1, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…